<DOC>
	<DOCNO>NCT02786485</DOCNO>
	<brief_summary>This Phase I , multicenter , open-label , non-randomized study match unrelated donor BPX-501 T cell infusion adult subject hematological malignancy present recurrent disease minimal residual disease ( MRD ) post-allogeneic transplant .</brief_summary>
	<brief_title>Study Matched Unrelated Donor T Cell Infusion Hematologic Malignancies After Allo-HSCT</brief_title>
	<detailed_description>Un-manipulated donor lymphocyte infusion ( DLI ) use stem cell transplantation treat prevent relapse , prevent infection establish full donor chimerism . The addition mature T cell exhibit broad repertoire T cell immunity viral antigen , well cancer antigen , might provide clinical benefit . However , expect side effect presence mature T cell potential occurrence acute graft-versus-host disease ( aGvHD ) . The use suicide gene switch would trigger initiation apoptosis alloreactive T cell infusion drug would represent potential optimal strategy restore early immunity build `` safety switch '' GvHD side effect . Evidence emerge low-dose DLI follow dose escalation achieve high clinical response rate lower GvHD occurrence . Optimization DLI dose schedule well strategy donor T-cell manipulation may lead consistent ability separate GvHD graft-versus-tumor ( GvT ) activity improve safety DLI treatment . Our strategy infuse escalate dos manipulate T cell ( donor provide original hematopoietic stem cell graft ) adult child recurrent minimal residual disease ( MRD ) hematologic malignancy post-allogeneic transplant accelerate immune reconstitution thus improve graft versus leukemic effect reduce severity GvHD .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Subjects age ≥ 18 yr ≤ 65 yr ; Clinical diagnosis one follow hematological malignancy : Leukemia Myelodysplastic Syndromes Lymphomas Multiple Myeloma Other highrisk hematological malignancy eligible stem cell transplantation per institutional standard ; Recurrent disease present ≥100 day , minimal residual disease ( MRD ) present ≥ 30 day follow hematopoietic stem cell transplant ( HSCT ) use match unrelated donor locate National Marrow Donor Program ( NMDP ) ; Life expectancy &gt; 10 week ; Signed donor patient/guardian inform consent ; A 8/8 genotypic identical match determine high resolution type follow genetic locus : human leukocyte antigen ( HLA ) A , HLAB , HLAC HLADRB1 ; Performance status : Karnofsky score &gt; 50 % ; Subjects adequate organ function measure : Bone marrow : &gt; 25 % donor Tcell chimerism posttransplant Absolute neutrophil count ( ANC ) &gt; 1 x 109/L Cardiac : leave ventricular ejection fraction ( LVEF ) rest ≥ 45 % Pulmonary : forced expiratory volume ( FEV ) 1 , force vital capacity ( FVC ) , diffusion capacity lunch carbon monoxide ( DLCO ) ≥ 50 % predict ( correct hemoglobin ) Hepatic : direct bilirubin ≤ 3x upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ≤ 5x ULN Renal : creatinine ≤ 2x ULN age . ≥ Grade II acute GVHD chronic extensive GVHD due previous allograft time screen ; Active central nervous system ( CNS ) involvement malignant cell ( ≤ 2 month prior consent ) ; Current uncontrolled bacterial , viral fungal infection ( currently take medication evidence progression clinical symptom radiologic finding ) ; principal investigator final arbiter criterion ; Positive HIV serology viral RNA ; Pregnancy ( positive serum β human chorionic gonadotropin [ HCG ] test ) breastfeeding ; Fertile men woman unwilling use effective form birth control abstinence one year transplantation ; Bovine product allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>BPX-501</keyword>
	<keyword>Rimiducid</keyword>
	<keyword>AP1903</keyword>
	<keyword>Hematological malignancy</keyword>
	<keyword>Hematologic disease</keyword>
	<keyword>Leukemias Myelodysplastic Syndromes</keyword>
	<keyword>Lymphomas</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>